BridgeBio Pharma, Inc. (NASDAQ: BBIO) shares plummeted 11.93% in pre-market trading on Wednesday, continuing the downward trend from Tuesday's 14.06% drop. The steep decline comes as investors react negatively to the company's disappointing second-quarter 2025 financial results.
The biopharmaceutical company reported a loss of $0.95 per share for Q2 2025, significantly missing the analyst consensus estimate of $0.81 per share. This represents a 17.43% larger loss than expected and only a slight improvement from the $1.06 per share loss in the same quarter last year. Moreover, BridgeBio's net loss attributable to common stockholders increased substantially to $181.9 million, compared to $73.5 million in Q2 2024.
Despite the disappointing bottom line, BridgeBio's top-line performance showed promise. The company reported quarterly revenue of $110.6 million, beating analyst expectations of $100.4 million by 10.10%. This marks a substantial increase from the $2.17 million reported in the same period last year, driven largely by $71.5 million in U.S. Attruby net product revenue. However, the market appears to be focusing on the widening losses, contributing to the continued downward pressure on the stock price in pre-market trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.